HRTX
Heron Therapeutics, Inc. /De/
$0.45
+0.02 (+4.65%)
At close · Jul 8
Market Cap
$84.32M
Shares
189,279,369
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.45
Open$0.43
Day$0.42–0.45
52W$0.38–2.28
Avg vol 30d4.3M
Short int41.9M · 22.1% float · 6.7d
Short vol40%
Last earningsMay 11, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−57%
below
Price vs 50-day avg
−38%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
4%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−70%
trailing
YTD return
−65%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 167 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.12% of float · ▲ +4.3% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
167 holders — mid 3-yr range
Squeeze score
86
high risk · 0–100
Fundamentals
EPS growth
−33%
Y/Y
Free cash flow
$-27.9M
Balance sheet
$28.6M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 11, 2026
Net Revenue
· 2026 Full-Year
Initiated
$173M – $183M
Adjusted EBITDA
· 2026 Full-Year
Initiated
$10M – $20M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−57%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 167 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.12% of float · ▲ +4.3% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
167 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 4%
52-wk high $2
vs 200-day avg -57%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| APONVIE Average Daily Units year-over-year growth | 70% | Q1 2026 | — |
| APONVIE demand units year-over-year growth | 68% | Q1 2026 | — |
| APONVIE medium-to-high PONV risk procedures | 5.8M | Q1 2026 | — |
| APONVIE ordering accounts year-over-year growth | 67% | Q1 2026 | — |
| APONVIE P&T approved accounts | 1,902 | Q1 2026 | — |
| CINVANTI cumulative demand units sold since launch | 5M | Q1 2026 | — |
| CINVANTI market share in the NK1 CINV category | 25% | Q1 2026 | — |
| IGNITE included target accounts expansion in January 2026 | 40% | January 2026 | — |
| IGNITE target accounts growth by year-end 2025 | 111% | year-end 2025 | — |
| ZYNRELEF demand units year-over-year growth | 22% | Q1 2026 | — |
| Aponvi average daily units growth | 70% | Q1 call | — |
| Aponvi demand unit growth | 68% | Q1 call | — |
| Aponvi ordering accounts | 371 | March Q1 call | — |
| Aponvi P&T approved accounts | 1,903 | Q1 call | — |
| IGNITE 1.0 accounts | 2,261 | second half of 2025 call | — |
| IGNITE 2.0 accounts | 3,109 | full year 2026 call | — |
| Sinvanti exit market share | 25% | Q1 call | — |
| Zinerlef demand unit growth | 22% | Q1 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HRTX
this stock
Heron Therapeutics, Inc. /De/
|
$84.32M | -65.4% | — | — | 22.1% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Congressional Trades
Sell
Member
Ashley Hinson Arenholz
- Amount
- $1.0K–$15.0K
- Traded
- Mar 31, 2021
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HRTX | +5.4% | +0.0% | -69.6% | +5.4% | -65.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +5.6% | -0.8% | -77.0% | +5.6% | -74.7% |